NPY receptors as potential targets for anti-obesity drug development.
about
Emerging role of the brain in the homeostatic regulation of energy and glucose metabolismNeural control of energy balance: translating circuits to therapiesCorexit-EC9527A Disrupts Retinol Signaling and Neuronal Differentiation in P19 Embryonal Pluripotent CellsShort neuropeptide F is a sleep-promoting inhibitory modulator.Position and length of fatty acids strongly affect receptor selectivity pattern of human pancreatic polypeptide analogues.The neuropeptide Y Y1 receptor knockdown modulates activator protein 1-involved feeding behavior in amphetamine-treated rats.Genetic effects on DNA methylation and its potential relevance for obesity in Mexican Americans.Correlation of c-fos protein expression with neuropeptide content in the lung of bronchial asthmatic rat.Neuropeptides and the microbiota-gut-brain axisLong-Term Over-Expression of Neuropeptide Y in Hypothalamic Paraventricular Nucleus Contributes to Adipose Tissue Insulin Resistance Partly via the Y5 ReceptorPeptides and their potential role in the treatment of diabetes and obesity.Discovery of Small-Molecule Modulators of the Human Y4 ReceptorNPY and stress 30 years later: the peripheral view.Neuropeptide Y inhibits the trigeminovascular pathway through NPY Y1 receptor: implications for migraine.Neuronal circuits that regulate feeding behavior and metabolism.Can neuropeptides treat obesity? A review of neuropeptides and their potential role in the treatment of obesity.Central functions of neuropeptide Y in mood and anxiety disorders.Role of the hypothalamus in the neuroendocrine regulation of body weight and composition during energy deficit.Neuropeptide Y Y1 receptor knockdown can modify glutathione peroxidase and c-AMP response element-binding protein in phenylpropanolamine-treated rats.Recent advances in the understanding of how neuropeptide Y and α-melanocyte stimulating hormone function in adipose physiology.Current views on neuropeptide Y and diabetes-related atherosclerosis.Discovery of a Novel Class of Bicyclo[3.1.0]hexanylpiperazines as Noncompetitive Neuropeptide Y Y1 Antagonists.Peptide modifications differentially alter G protein-coupled receptor internalization and signaling bias.Functional polymorphism in the neuropeptide Y gene promoter (rs16147) is associated with serum leptin levels and waist-hip ratio in women.[(3)H]UR-PLN196: a selective nonpeptide radioligand and insurmountable antagonist for the neuropeptide Y Y(2) receptor.Modulation of feeding by chronic rAAV expression of a relaxin-3 peptide agonist in rat hypothalamus.Neuropeptide Y Regulates Sleep by Modulating Noradrenergic Signaling.Cloning, phylogeny, and regional expression of a Y5 receptor mRNA in the brain of the sea lamprey (Petromyzon marinus).Targeted Orexin and Hypothalamic Neuropeptides for Migraine.An engineered calmodulin-based allosteric switch for Peptide biosensing.Structural basis of ligand binding modes at the neuropeptide Y Y1 receptor.Pharmacokinetics and Tolerability of Exenatide Delivered by 7-Day Continuous Subcutaneous Infusion in Healthy Volunteers.Cell-type-specific interrogation of CeA Drd2 neurons to identify targets for pharmacological modulation of fear extinction
P2860
Q26766494-A02599E7-8189-4176-B71B-E7A88C517881Q27005992-F5DE40F0-106F-4BE6-B1F8-634DA1D56777Q28390415-0D138106-4D5C-4BD9-9D0C-16E43B24055AQ30549666-44D619E8-2D0E-4EE0-9FFD-885D53234E5DQ33919544-3862CAC9-5BEA-420D-98FF-67C6AFAC264EQ34480148-02E86C6A-3E9E-41AE-9B1C-AD17EAD22411Q34994466-F74E0E0E-8AFD-4898-8EA3-00D978F453A3Q35038639-C2533FCF-DDBD-4DBC-81AA-5CF4EDC2C256Q35178233-0982D4AB-B8C6-4559-A2D2-1ED304CE1F15Q35620798-4E0AD6A8-A870-4C2A-8BC4-92B4D6B721AFQ35760298-FE96D6CB-CEE9-46EE-A164-DB638842CCD3Q36050350-3DB6751E-9501-4B79-B992-7C0DC330965AQ36382828-26CA810D-BF38-43E0-BCE5-C275CE403D05Q37104106-FF4F2B0B-D6E4-4DF8-93CC-197450433C5EQ37161389-CCCFB0F2-36AC-49DB-B01D-B97569AF81D6Q37337828-B890BD80-3673-4287-9900-39CC5EADBC87Q37945311-06B24DE6-509F-4768-A1C4-93F847E6DCE4Q37954380-33463722-4412-47FE-801B-CD8E2A424A93Q38320911-DA8AE615-1DF5-4432-8363-28A4D6419762Q39044029-72034DFC-9693-4FD7-A80C-E84EA7663463Q39250869-F713B21C-940E-490E-9E02-BF847A5F3740Q39735921-ECDAA8EA-112B-40A2-AF28-F96337951664Q42031030-87B8620B-DD87-4D37-8A88-809A4BF03935Q43699710-43CD014B-22D1-4133-B520-FF2BE2941918Q44483229-48B436DA-5ECC-4544-A6A2-1493C138862CQ45882999-E51C57EF-C90D-484D-8689-055B153D3056Q46248439-9EC57D10-C284-4919-9876-387CBA6514A6Q48932737-23D3BE4B-3163-4C1A-AB41-0D1D888FB300Q50016389-81C761DB-EC62-48E0-88B3-FED7031413B4Q50859778-30659890-7774-4E65-9E06-A26291CDA947Q52316530-8D2A577D-64EF-4235-AEE8-A508697E16E4Q53186529-06A90D89-415C-44F3-8875-F806F638FCD9Q58721696-F7305F8C-29F4-4788-98EE-42434E435563
P2860
NPY receptors as potential targets for anti-obesity drug development.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
NPY receptors as potential targets for anti-obesity drug development.
@ast
NPY receptors as potential targets for anti-obesity drug development.
@en
type
label
NPY receptors as potential targets for anti-obesity drug development.
@ast
NPY receptors as potential targets for anti-obesity drug development.
@en
prefLabel
NPY receptors as potential targets for anti-obesity drug development.
@ast
NPY receptors as potential targets for anti-obesity drug development.
@en
P2860
P1476
NPY receptors as potential targets for anti-obesity drug development.
@en
P2093
Herbert Herzog
P2860
P304
P356
10.1111/J.1476-5381.2011.01363.X
P407
P577
2011-07-01T00:00:00Z